JP2015523962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523962A5 JP2015523962A5 JP2015510445A JP2015510445A JP2015523962A5 JP 2015523962 A5 JP2015523962 A5 JP 2015523962A5 JP 2015510445 A JP2015510445 A JP 2015510445A JP 2015510445 A JP2015510445 A JP 2015510445A JP 2015523962 A5 JP2015523962 A5 JP 2015523962A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antigen
- amino acid
- fel
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642083P | 2012-05-03 | 2012-05-03 | |
| US61/642,083 | 2012-05-03 | ||
| US201261718044P | 2012-10-24 | 2012-10-24 | |
| US61/718,044 | 2012-10-24 | ||
| US201361783312P | 2013-03-14 | 2013-03-14 | |
| US61/783,312 | 2013-03-14 | ||
| PCT/US2013/039192 WO2013166236A1 (en) | 2012-05-03 | 2013-05-02 | Human antibodies to fel d1 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017116808A Division JP6603269B2 (ja) | 2012-05-03 | 2017-06-14 | Ｆｅｌ ｄ１に対するヒト抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523962A JP2015523962A (ja) | 2015-08-20 |
| JP2015523962A5 true JP2015523962A5 (enExample) | 2016-06-16 |
| JP6400569B2 JP6400569B2 (ja) | 2018-10-03 |
Family
ID=48326501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510445A Active JP6400569B2 (ja) | 2012-05-03 | 2013-05-02 | Ｆｅｌｄ１に対するヒト抗体およびその使用方法 |
| JP2017116808A Active JP6603269B2 (ja) | 2012-05-03 | 2017-06-14 | Ｆｅｌ ｄ１に対するヒト抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017116808A Active JP6603269B2 (ja) | 2012-05-03 | 2017-06-14 | Ｆｅｌ ｄ１に対するヒト抗体およびその使用方法 |
Country Status (33)
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090137416A1 (en) | 2001-01-16 | 2009-05-28 | Regeneron Pharmaceuticals, Inc. | Isolating Cells Expressing Secreted Proteins |
| DK3241435T3 (da) | 2009-07-08 | 2021-08-23 | Kymab Ltd | Dyremodeller og terapeutiske molekyler |
| AU2012311286B2 (en) | 2011-09-19 | 2018-07-26 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| EP3036543B1 (en) * | 2013-08-23 | 2019-06-19 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| WO2015049517A2 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| ES2809455T3 (es) | 2014-11-17 | 2021-03-04 | Regeneron Pharma | Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20 |
| DK3277725T3 (da) | 2015-03-30 | 2021-01-11 | Regeneron Pharma | Konstante tungkædeområder med reduceret binding til FC-gammareceptorer |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| CN108025059B (zh) * | 2015-09-08 | 2022-09-09 | 苏黎世大学 | 抗猫过敏的组合物 |
| BR112018071307A2 (pt) | 2016-04-18 | 2019-02-26 | Celldex Therapeutics, Inc. | anticorpos agonistas que ligam cd40 humana e usos dos mesmos |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| PL3558347T3 (pl) * | 2016-12-22 | 2026-04-20 | Regeneron Pharmaceuticals, Inc. | Sposób leczenia alergii swoistymi dla alergenu przeciwciałami monoklonalnymi |
| BR112019015145A2 (pt) * | 2017-01-24 | 2020-03-24 | Société des Produits Nestlé S.A. | Composições que compreendem anticorpos anti-fel d1 e métodos para reduzir pelo menos um sintoma da alergia de humanos a gatos |
| KR20210084695A (ko) | 2017-07-06 | 2021-07-07 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| GB201710984D0 (en) | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
| US20190194298A1 (en) | 2017-12-22 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| CA3085177A1 (en) | 2018-01-31 | 2019-08-08 | Regeneron Pharamaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| AU2019227531B2 (en) | 2018-02-28 | 2025-01-30 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US11054389B2 (en) | 2018-03-19 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| CN119823260A (zh) * | 2018-05-18 | 2025-04-15 | 陈扎克伯格生物中心旧金山公司 | 从人中分离过敏原特异性抗体的方法及其用途 |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| WO2020047067A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| JP2022517720A (ja) | 2019-01-16 | 2022-03-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ジスルフィド結合を特徴付けるための方法 |
| JP7541534B2 (ja) | 2019-05-13 | 2024-08-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改善された競合的リガンド結合アッセイ |
| KR20260058863A (ko) | 2019-09-24 | 2026-04-29 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| CA3165060C (en) | 2020-01-21 | 2023-06-20 | Yiming Zhao | Deglycosylation methods for electrophoresis of glycosylated proteins |
| EP4204449A1 (en) | 2020-08-26 | 2023-07-05 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| KR20230058094A (ko) | 2020-08-31 | 2023-05-02 | 리제너론 파아마슈티컬스, 인크. | 세포 배양 성능을 개선하고 아스파라긴 서열 변이체를 완화하기 위한 아스파라긴 공급 전략 |
| EP4251128A1 (en) | 2020-11-25 | 2023-10-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| IL303675A (en) | 2020-12-17 | 2023-08-01 | Regeneron Pharma | Production of protein thermal microgels |
| MX2023008527A (es) | 2021-01-20 | 2023-07-28 | Regeneron Pharma | Metodos para mejorar el valor proteico en cultivo celular. |
| TW202246325A (zh) | 2021-03-03 | 2022-12-01 | 美商再生元醫藥公司 | 用於定量及修飾蛋白質黏度之系統及方法 |
| EP4305190A4 (en) | 2021-03-11 | 2025-03-26 | Iggenix, Inc. | METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION |
| EP4315344A1 (en) | 2021-03-26 | 2024-02-07 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing mixing protocols |
| AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| AR127006A1 (es) | 2021-09-08 | 2023-12-06 | Regeneron Pharma | UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc |
| AU2022348521A1 (en) | 2021-09-20 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| EP4413364A2 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods of ph modeling and control |
| EP4413359A1 (en) | 2021-10-07 | 2024-08-14 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
| WO2023076340A1 (en) | 2021-10-26 | 2023-05-04 | Regeneron Pharmaceuticals, Inc. | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| CN114113278B (zh) * | 2021-11-24 | 2024-08-02 | 中国计量科学研究院 | 一种基于质谱的体外诊断试剂抗体的表位定位方法 |
| US20230174632A1 (en) * | 2021-12-08 | 2023-06-08 | IgGenix, Inc. | Combinations for allergy therapy |
| EP4493921A1 (en) | 2022-03-18 | 2025-01-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
| US20230416349A1 (en) | 2022-06-23 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | Methods Of Identifying And Evaluating Cat Allergy Gene Signatures In A Subject By Determining A Stratified Score Based On Gene Expression |
| EP4634659A1 (en) | 2022-12-16 | 2025-10-22 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| US20240248097A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| EP4669963A2 (en) | 2023-02-22 | 2025-12-31 | Regeneron Pharmaceuticals, Inc. | SYSTEM FITNESS PARAMETERS AND COLUMN AGING |
| AU2024229494A1 (en) | 2023-03-01 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Anti-fel d1 antibody formulations |
| CN121241065A (zh) | 2023-03-31 | 2025-12-30 | 爱尔开-阿贝优公司 | 适用于治疗树木花粉过敏的过敏原结合抗体 |
| JP2026514305A (ja) | 2023-05-01 | 2026-05-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | フェノールまたはベンジルアルコールを使用した複数回投与抗体医薬品 |
| CN117004650B (zh) * | 2023-06-25 | 2024-05-14 | 山东立菲生物产业有限公司 | 一种猫皮屑过敏原组分feld1双链二聚体重组蛋白、制备方法及应用 |
| US20250086164A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| EP4780828A2 (en) | 2023-09-18 | 2026-07-29 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| CN117069865B (zh) * | 2023-10-12 | 2024-03-01 | 中国农业科学院饲料研究所 | 一种基于T细胞抗原表位猫过敏原蛋白嵌合肽cFel d 1的原核表达及其卵黄抗体的制备 |
| CN122138969A (zh) | 2023-10-18 | 2026-06-02 | 瑞泽恩制药公司 | 从过程中上游细胞培养物材料中快速纯化单克隆抗体 |
| AU2024373307A1 (en) | 2023-11-02 | 2026-05-14 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| TW202600593A (zh) | 2024-02-16 | 2026-01-01 | 美商再生元醫藥公司 | 製造濃縮配製包括蛋白質之藥品物質之方法，以及該方法製造之濃縮配製之藥品物質 |
| TW202602489A (zh) | 2024-03-15 | 2026-01-16 | 美商再生元醫藥公司 | 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐 |
| CN117964767B (zh) * | 2024-03-29 | 2024-08-06 | 北京恩泽康泰生物科技有限公司 | 抗rage抗体、细胞外囊泡及其制备方法和应用 |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
| WO2026060350A1 (en) | 2024-09-13 | 2026-03-19 | Regeneron Pharmaceuticals, Inc. | Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods |
| WO2026076201A2 (en) | 2024-10-03 | 2026-04-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools |
| WO2026080597A1 (en) | 2024-10-08 | 2026-04-16 | Regeneron Pharmaceuticals, Inc. | Sustained delivery of biologics and non-aqueous manufacture of same |
| WO2026112457A2 (en) | 2024-11-21 | 2026-05-28 | Regeneron Pharmaceuticals, Inc. | Heterodimeric antigen-binding molecules that bind to viral particles and uses thereof |
| WO2026136650A1 (en) | 2024-12-20 | 2026-06-25 | Regeneron Pharmaceuticals, Inc. | Fixed seed train schedule for improved protein production |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5512283A (en) | 1990-07-06 | 1996-04-30 | Allergene, Inc. | Methods for the selective suppression of an immune response to dust mite der Pi |
| CA2128331A1 (en) * | 1992-01-21 | 1993-07-22 | Julia L. Greenstein | Methods for using histamine derivatives as immunomodulators and in immunotherapeutics |
| WO1994014475A1 (en) * | 1992-12-21 | 1994-07-07 | Tanox Biosystems, Inc. | ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT |
| GB0002386D0 (en) | 2000-02-02 | 2000-03-22 | Novartis Nutrition Ag | Therapeutic composition |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ES2424229T3 (es) * | 2005-03-18 | 2013-09-30 | Cytos Biotechnology Ag | Proteínas de fusión de alérgenos de gato y utilización de las mismas |
| US7566456B2 (en) * | 2005-06-23 | 2009-07-28 | Haiming Chen | Allergen vaccine proteins for the treatment and prevention of allergic diseases |
| GB0513878D0 (en) * | 2005-07-06 | 2005-08-10 | Mars Inc | Cat allergen |
| WO2007065633A1 (en) | 2005-12-05 | 2007-06-14 | Imvision Ag | Modulation of the immune response by administration of intralymphatic transduction allergen (itag) -molecules |
| WO2007113633A2 (en) | 2006-04-03 | 2007-10-11 | Pfizer Products Inc. | Immunogenic compositions comprising cat allergen fel dl |
| ATE537190T1 (de) | 2006-06-02 | 2011-12-15 | Regeneron Pharma | Hochaffine antikörper gegen den humanen il-6- rezeptor |
| AT503690A1 (de) * | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| EP1921142A1 (en) * | 2006-11-07 | 2008-05-14 | Cytos Biotechnology AG | Selection of human monoclonal antibodies by eukaryotic cell display |
| RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| EP2626372B1 (en) * | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| AU2008255352B2 (en) * | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| GB0710529D0 (en) | 2007-06-01 | 2007-07-11 | Circassia Ltd | Vaccine |
| ES2635870T3 (es) * | 2007-07-09 | 2017-10-05 | Nestec S.A. | Métodos para reducir las alergias provocadas por alérgenos ambientales |
| PL2187964T3 (pl) * | 2007-08-10 | 2015-03-31 | Regeneron Pharma | Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| MX366337B (es) | 2010-10-06 | 2019-07-05 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r). |
| JO3820B1 (ar) * | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| EP3036543B1 (en) | 2013-08-23 | 2019-06-19 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| PL3558347T3 (pl) | 2016-12-22 | 2026-04-20 | Regeneron Pharmaceuticals, Inc. | Sposób leczenia alergii swoistymi dla alergenu przeciwciałami monoklonalnymi |
-
2013
- 2013-05-01 JO JOP/2013/0131A patent/JO3820B1/ar active
- 2013-05-02 ES ES13721544T patent/ES2780392T3/es active Active
- 2013-05-02 SM SM20200241T patent/SMT202000241T1/it unknown
- 2013-05-02 SG SG10201608378UA patent/SG10201608378UA/en unknown
- 2013-05-02 PL PL21194412.9T patent/PL3978522T3/pl unknown
- 2013-05-02 SG SG10202102919XA patent/SG10202102919XA/en unknown
- 2013-05-02 TW TW106119738A patent/TW201803901A/zh unknown
- 2013-05-02 CN CN201910294004.8A patent/CN110240651B/zh active Active
- 2013-05-02 SI SI201332111T patent/SI3978522T1/sl unknown
- 2013-05-02 HR HRP20211932TT patent/HRP20211932T1/hr unknown
- 2013-05-02 SM SM20250396T patent/SMT202500396T1/it unknown
- 2013-05-02 NZ NZ733480A patent/NZ733480A/en unknown
- 2013-05-02 FI FIEP21194412.9T patent/FI3978522T3/fi active
- 2013-05-02 PL PL19218187T patent/PL3660047T3/pl unknown
- 2013-05-02 AU AU2013256251A patent/AU2013256251C1/en active Active
- 2013-05-02 IN IN8767DEN2014 patent/IN2014DN08767A/en unknown
- 2013-05-02 HU HUE19218187A patent/HUE057062T2/hu unknown
- 2013-05-02 LT LTEP21194412.9T patent/LT3978522T/lt unknown
- 2013-05-02 BR BR122019023685-2A patent/BR122019023685B1/pt active IP Right Grant
- 2013-05-02 LT LTEP19218187.3T patent/LT3660047T/lt unknown
- 2013-05-02 PT PT137215448T patent/PT2844672T/pt unknown
- 2013-05-02 BR BR112014026852-5A patent/BR112014026852B1/pt active IP Right Grant
- 2013-05-02 ES ES21194412T patent/ES3049982T3/es active Active
- 2013-05-02 DK DK21194412.9T patent/DK3978522T3/da active
- 2013-05-02 MY MYPI2014002857A patent/MY164101A/en unknown
- 2013-05-02 US US13/875,401 patent/US9079948B2/en active Active
- 2013-05-02 AR ARP130101494A patent/AR090914A1/es unknown
- 2013-05-02 EP EP13721544.8A patent/EP2844672B1/en active Active
- 2013-05-02 CN CN201380035000.9A patent/CN104411719B/zh active Active
- 2013-05-02 PT PT211944129T patent/PT3978522T/pt unknown
- 2013-05-02 KR KR1020147033137A patent/KR102185516B1/ko active Active
- 2013-05-02 EP EP25194366.8A patent/EP4653056A3/en active Pending
- 2013-05-02 SI SI201331698T patent/SI2844672T1/sl unknown
- 2013-05-02 EP EP21194412.9A patent/EP3978522B1/en active Active
- 2013-05-02 NZ NZ701124A patent/NZ701124A/en unknown
- 2013-05-02 CA CA2871077A patent/CA2871077C/en active Active
- 2013-05-02 TW TW102115645A patent/TWI644921B/zh active
- 2013-05-02 SI SI201331935T patent/SI3660047T1/sl unknown
- 2013-05-02 RU RU2014148502A patent/RU2658491C2/ru active
- 2013-05-02 RS RS20200539A patent/RS60282B1/sr unknown
- 2013-05-02 MX MX2014013371A patent/MX377634B/es active IP Right Grant
- 2013-05-02 MY MYPI2020006733A patent/MY195564A/en unknown
- 2013-05-02 PT PT192181873T patent/PT3660047T/pt unknown
- 2013-05-02 SM SM20220014T patent/SMT202200014T1/it unknown
- 2013-05-02 PL PL13721544T patent/PL2844672T3/pl unknown
- 2013-05-02 LT LTEP13721544.8T patent/LT2844672T/lt unknown
- 2013-05-02 MY MYPI2017701565A patent/MY181422A/en unknown
- 2013-05-02 SG SG11201406748QA patent/SG11201406748QA/en unknown
- 2013-05-02 DK DK13721544.8T patent/DK2844672T3/da active
- 2013-05-02 HR HRP20251429TT patent/HRP20251429T1/hr unknown
- 2013-05-02 RS RS20211475A patent/RS62636B1/sr unknown
- 2013-05-02 WO PCT/US2013/039192 patent/WO2013166236A1/en not_active Ceased
- 2013-05-02 HR HRP20200652TT patent/HRP20200652T1/hr unknown
- 2013-05-02 RS RS20251155A patent/RS67417B1/sr unknown
- 2013-05-02 ES ES19218187T patent/ES2898372T3/es active Active
- 2013-05-02 HU HUE13721544A patent/HUE049440T2/hu unknown
- 2013-05-02 JP JP2015510445A patent/JP6400569B2/ja active Active
- 2013-05-02 EP EP19218187.3A patent/EP3660047B1/en active Active
- 2013-05-03 UY UY34782A patent/UY34782A/es active IP Right Grant
-
2014
- 2014-10-08 ZA ZA2014/07302A patent/ZA201407302B/en unknown
- 2014-10-19 IL IL235121A patent/IL235121B/en active IP Right Grant
- 2014-11-03 MX MX2020003864A patent/MX2020003864A/es unknown
-
2015
- 2015-06-05 US US14/732,578 patent/US9475869B2/en active Active
-
2016
- 2016-09-13 US US15/263,848 patent/US10047152B2/en active Active
-
2017
- 2017-01-26 US US15/416,176 patent/US10047153B2/en active Active
- 2017-06-14 JP JP2017116808A patent/JP6603269B2/ja active Active
-
2018
- 2018-05-03 AU AU2018203087A patent/AU2018203087B9/en active Active
- 2018-07-05 US US16/028,275 patent/US11174305B2/en active Active
-
2020
- 2020-05-04 CY CY20201100408T patent/CY1124023T1/el unknown
- 2020-08-25 ZA ZA2020/05273A patent/ZA202005273B/en unknown
-
2021
- 2021-10-13 US US17/500,418 patent/US12252530B2/en active Active
- 2021-12-20 CY CY20211101115T patent/CY1124819T1/el unknown
-
2022
- 2022-03-09 ZA ZA2022/02846A patent/ZA202202846B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014148502A (ru) | Человеческие антитела к fel d1 и способы их применения | |
| JP7162097B2 (ja) | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 | |
| JP2022526738A5 (enExample) | ||
| KR102307248B1 (ko) | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 | |
| KR102492826B1 (ko) | Il-4r 억제제를 투여함으로써 알레르기 치료 및 알레르겐 특이적 면역요법을 강화시키는 방법 | |
| JP2018500014A5 (enExample) | ||
| JP2015503909A5 (enExample) | ||
| JP2019531273A5 (enExample) | ||
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| JP2006528626A5 (enExample) | ||
| US20250034272A1 (en) | Compositions and methods for treating severe asthma | |
| JP2020522280A5 (enExample) | ||
| JP2020531003A5 (enExample) | ||
| JP2021533806A5 (enExample) | ||
| Garg et al. | A Complete Sojourn of Monoclonal Antibodies: AI, Rare Diseases/Disorders and Immunotoxic Effects | |
| NZ779309A (en) | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy | |
| NZ779309B2 (en) | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy | |
| JP2024513376A5 (enExample) | ||
| RU2021128133A (ru) | Введение ингибиторов pd-1 для лечения рака кожи | |
| TH1901007314A (th) | แอนติบอดีของมนุษย์ที่จับกับ bet v 1 และวิธีการใช้ของสิ่งนั้น |